Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE, USA.
J Cell Mol Med. 2011 Jul;15(7):1433-42. doi: 10.1111/j.1582-4934.2011.01279.x.
The role of telomeres and telomerase as a target for cancer therapeutics is an area of continuing interest. This review is intended to provide an update on the field, pointing to areas in which our knowledge remains deficient and exploring the details of the most promising areas being advanced into clinical trials. Topics that will be covered include the role of dysfunctional telomeres in cellular aging and how replicative senescence provides an initial barrier to the emergence of immortalized cells, a hallmark of cancer. As an important translational theme, this review will consider possibilities for selectively targeting telomeres and telomerase to enhance cancer therapy. The role of telomerase as an immunotherapy, as a gene therapy approach using telomerase promoter driven oncolytic viruses and as a small oligonucleotide targeted therapy (Imetelstat) will be discussed.
端粒和端粒酶作为癌症治疗靶点的作用是一个持续关注的领域。这篇综述旨在提供该领域的最新信息，指出我们知识仍然不足的领域，并探讨正在推进临床试验的最有前途的领域的细节。将涵盖的主题包括功能失调的端粒在细胞衰老中的作用，以及复制性衰老如何为永生细胞的出现提供最初的障碍，这是癌症的一个标志。作为一个重要的转化主题，本综述将考虑选择性靶向端粒和端粒酶以增强癌症治疗的可能性。端粒酶作为免疫疗法的作用，以及使用端粒酶启动子驱动溶瘤病毒的基因治疗方法和作为靶向小寡核苷酸的治疗方法（imetelstat）将进行讨论。
